Impact of Eprazole Sodium combined with somatostatin on treatment efficacy and coagulation function of patients with upper gastrointestinal bleeding: A retrospective study

TL;DR

Combining eprazole sodium with somatostatin improves treatment outcomes and coagulation in patients with upper gastrointestinal bleeding.

Contribution

The study demonstrates that combining eprazole sodium with somatostatin improves treatment efficacy and coagulation function in upper gastrointestinal bleeding patients.

Findings

The study group showed higher treatment efficacy (96.30%) compared to the control group (84.31%).

The study group had shorter hemostasis time, lower blood transfusion volume, and shorter hospital stay.

The study group showed better coagulation function with higher fibrinogen and lower PT, TT, and APTT levels.

Abstract

To investigate the impact of eprazole sodium combined with somatostatin on the coagulation function and treatment efficacy of patients with upper gastrointestinal bleeding.

In this single-center retrospective observational study, clinical data of 105 patients with upper gastrointestinal bleeding admitted to The First People’s Hospital of Yongkang (Jinhua, Zhejiang, China) from April 2023 to March 2025 were analyzed. Fifty-one patients who were treated with somatostatin and omeprazole comprised the control group. Fifty-four patients who received eprazole sodium in combination with somatostatin were included in the study group. The treatment effect, rehabilitation index (time of hemostasis, blood transfusion volume, length of hospitalization), coagulation function [fibrinogen (FIB), prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT)] level, and adverse reaction rate were compared.

The total efficacy of the study group (96.30%) was higher than that of the control group (84.31%), while the duration of hemostasis, volume of blood transfusion, and length of hospital stay were lower (P<0.05). After treatment, the levels of FIB were higher, while PT, TT, and APTT levels decreased in both groups. The posttreatment levels of FIB in the study group were considerably higher than in the control group, while the levels of PT, TT, and APTT were significantly lower (P<0.05). The incidence of adverse reactions was comparable in the two groups (P>0.05).

In patients with upper gastrointestinal bleeding, the combination of eprazole sodium and somatostatin can effectively shorten the hemostasis time, reduce the blood transfusion volume, improve the coagulation function, improve the overall treatment effect, promote early recovery and discharge without increasing the risk of adverse reactions.